[go: up one dir, main page]

UA85702C2 - 3-[ 4-гетероциклил-1,2,3-триазол-1-ил]-n-арилбензамиды как ингибиторы продуцирования цитокинов, предназначены для лечения хронических воспалительных заболеваний - Google Patents

3-[ 4-гетероциклил-1,2,3-триазол-1-ил]-n-арилбензамиды как ингибиторы продуцирования цитокинов, предназначены для лечения хронических воспалительных заболеваний

Info

Publication number
UA85702C2
UA85702C2 UAA200610490A UAA200610490A UA85702C2 UA 85702 C2 UA85702 C2 UA 85702C2 UA A200610490 A UAA200610490 A UA A200610490A UA A200610490 A UAA200610490 A UA A200610490A UA 85702 C2 UA85702 C2 UA 85702C2
Authority
UA
Ukraine
Prior art keywords
chronic inflammatory
benzamides
triazol
heterocyclyl
inhibitors
Prior art date
Application number
UAA200610490A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дерек Коган
Минг-Хонг Хао
Виктор Марк Ками
Крейг Эндрю Миллер
Метью Расселл Недертон
Алан Девид Свинаймер
Original Assignee
Бёрингер Ингельхайм Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фармасьютикалз, Инк. filed Critical Бёрингер Ингельхайм Фармасьютикалз, Инк.
Publication of UA85702C2 publication Critical patent/UA85702C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

В заявке описаны соединения формулы, (I)которые ингибируют продуцирование цитокинов, которые принимают участие в воспалительных процессах, и поэтому применимы для лечения заболеваний и патологических состояний, которые включают воспаления, таких как хроническое воспалительное заболевание.Также описаны способы получения этих соединений и фармацевтические композиции, которые включают эти соединения.
UAA200610490A 2004-03-09 2005-04-03 3-[ 4-гетероциклил-1,2,3-триазол-1-ил]-n-арилбензамиды как ингибиторы продуцирования цитокинов, предназначены для лечения хронических воспалительных заболеваний UA85702C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55144504P 2004-03-09 2004-03-09

Publications (1)

Publication Number Publication Date
UA85702C2 true UA85702C2 (ru) 2009-02-25

Family

ID=34962594

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200610490A UA85702C2 (ru) 2004-03-09 2005-04-03 3-[ 4-гетероциклил-1,2,3-триазол-1-ил]-n-арилбензамиды как ингибиторы продуцирования цитокинов, предназначены для лечения хронических воспалительных заболеваний

Country Status (30)

Country Link
US (2) US7214802B2 (ru)
EP (2) EP1887003A1 (ru)
JP (1) JP4850824B2 (ru)
KR (1) KR20060129077A (ru)
CN (1) CN1930144A (ru)
AR (1) AR048315A1 (ru)
AT (1) ATE432273T1 (ru)
AU (1) AU2005223738B2 (ru)
BR (1) BRPI0508561A (ru)
CA (1) CA2557856C (ru)
CY (1) CY1109333T1 (ru)
DE (1) DE602005014621D1 (ru)
DK (1) DK1725544T3 (ru)
EA (1) EA011634B1 (ru)
EC (1) ECSP066833A (ru)
ES (1) ES2327940T3 (ru)
HR (1) HRP20090334T1 (ru)
IL (1) IL177937A0 (ru)
MY (1) MY143000A (ru)
NO (1) NO20064120L (ru)
NZ (1) NZ550148A (ru)
PE (1) PE20051146A1 (ru)
PL (1) PL1725544T3 (ru)
PT (1) PT1725544E (ru)
RS (1) RS50796B (ru)
SI (1) SI1725544T1 (ru)
TW (1) TW200602313A (ru)
UA (1) UA85702C2 (ru)
WO (1) WO2005090333A1 (ru)
ZA (1) ZA200606177B (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858804B2 (en) 2006-04-18 2010-12-28 Boehringer Ingelheim International Gmbh Process for making cytokine inhibiting compounds containing 4- and 5-imidazolyl rings and the intermediates thereof
BRPI0712795A2 (pt) * 2006-07-07 2012-09-04 Boehringer Ingelheim Int derivados de heteroarila substituìdos com fenila e uso dos mesmos como agentes antitumorais
EP2090570B1 (en) 2006-09-05 2011-11-09 Kyowa Hakko Kirin Co., Ltd. Imidazole derivative
US20100240657A1 (en) * 2007-07-02 2010-09-23 Boehringer Ingelheim International Gmbh Chemical compounds
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
US8278340B2 (en) 2007-11-27 2012-10-02 North Carolina State University Inhibition of biofilms in plants with imidazole derivatives
US9005643B2 (en) * 2008-04-04 2015-04-14 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
US7897631B2 (en) * 2008-04-21 2011-03-01 North Carolina State University Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives
AU2009289329A1 (en) * 2008-09-02 2010-03-11 Neurosearch A/S Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
JP5603869B2 (ja) * 2008-09-29 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
AR073701A1 (es) 2008-09-29 2010-11-24 Abbott Lab Derivados de indol y de indolicina, metodos para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades neurodegenerativas.
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US20110294668A1 (en) 2008-12-08 2011-12-01 North Carolina State University Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives
US8569316B2 (en) 2009-02-17 2013-10-29 Boehringer Ingelheim International Gmbh Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
US9221765B2 (en) 2009-06-10 2015-12-29 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
WO2011008312A2 (en) 2009-07-14 2011-01-20 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
US8778959B2 (en) 2009-12-17 2014-07-15 Abbvie Inc. AZA-bridged ring-fused indoles and indolines
CA2782361C (en) 2009-12-17 2018-01-16 Abbott Laboratories Bridgehead amine ring-fused indoles and indolines useful to treat neurodegenerative and neuropsychiatric disorders
US8809532B2 (en) 2009-12-17 2014-08-19 Abbvie Inc. Aza-ring fused indole and indoline derivatives
JP2013516480A (ja) 2010-01-07 2013-05-13 セレクサゲン セラピューティクス，インク． ヘッジホッグ阻害剤
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
US8466181B2 (en) * 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
UA110048C2 (uk) * 2011-01-28 2015-11-10 Інгібування il17 і ifn-гамма для лікування аутоімунного запалення
US8592456B2 (en) * 2011-01-28 2013-11-26 4Sc Discovery Gmbh IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8859549B2 (en) 2011-05-13 2014-10-14 Abbvie, Inc. Potassium channel modulators
JP6054869B2 (ja) 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
BR112016010164A2 (pt) 2013-11-05 2017-08-08 Bayer Cropscience Ag novos compostos para o combate aos ártropodes
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
US11724997B2 (en) 2018-03-01 2023-08-15 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
EP3817811B1 (en) * 2018-07-04 2024-04-03 Boehringer Ingelheim International GmbH Triazole benzamide derivatives as gpr142 agonists
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EA202191422A1 (ru) 2018-11-21 2021-10-21 Кейс Вестерн Ризерв Юниверсити Композиции и способы модулирования активности короткоцепочечной дегидрогеназы
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
PH12022550361A1 (en) 2019-08-14 2023-02-27 Incyte Corp Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
PE20221905A1 (es) 2019-10-11 2022-12-23 Incyte Corp Aminas biciclicas como inhibidoras de la cdk2
MX2023006578A (es) * 2020-12-04 2023-07-31 Eubulus Biotherapeutics Inc Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas.
CN116761801A (zh) * 2021-03-12 2023-09-15 四川科伦博泰生物医药股份有限公司 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US20240383860A1 (en) 2021-11-19 2024-11-21 Nippon Soda Co., Ltd. Method for producing 2-alkylthio-1-imidazoylethanone compound
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
ES2239357T3 (es) * 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
JP4385414B2 (ja) * 1997-10-13 2009-12-16 アステラス製薬株式会社 アミド若しくはアミン誘導体
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
EP1068187A1 (en) * 1998-04-08 2001-01-17 Abbott Laboratories Pyrazole inhibitors of cytokine production
US6506747B1 (en) * 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
USRE44735E1 (en) 1998-10-13 2014-01-28 Covidien Lp Multi-channel non-invasive tissue oximeter
BR9915534B1 (pt) 1998-10-23 2011-04-19 1-piridil substituìdo)-1,2,4-triazóis inseticidas.
US6451820B1 (en) * 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US6498423B1 (en) 2001-06-27 2002-12-24 Welch Allyn, Inc. Lamp thermal control by directed air flow
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
ATE511840T1 (de) 2001-10-09 2011-06-15 Amgen Inc Imidazolderivate als entzündungshemmende mittel
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
BRPI0409949A (pt) * 2003-05-01 2006-04-25 Bristol Myers Squibb Co compostos de pirazol amida aril-substituìda úteis como inibidores de cinase

Also Published As

Publication number Publication date
EA200601571A1 (ru) 2007-02-27
BRPI0508561A (pt) 2007-08-14
CN1930144A (zh) 2007-03-14
EP1725544B1 (en) 2009-05-27
WO2005090333A8 (en) 2006-08-24
CA2557856A1 (en) 2005-09-29
DK1725544T3 (da) 2009-07-27
EP1887003A1 (en) 2008-02-13
NO20064120L (no) 2006-09-26
ZA200606177B (en) 2008-12-31
SI1725544T1 (sl) 2009-10-31
CA2557856C (en) 2010-06-29
JP2007528395A (ja) 2007-10-11
US20060079519A1 (en) 2006-04-13
NZ550148A (en) 2010-07-30
IL177937A0 (en) 2006-12-31
PL1725544T3 (pl) 2009-10-30
JP4850824B2 (ja) 2012-01-11
KR20060129077A (ko) 2006-12-14
HRP20090334T1 (en) 2009-07-31
AU2005223738B2 (en) 2011-08-11
PT1725544E (pt) 2009-07-02
AU2005223738A1 (en) 2005-09-29
PE20051146A1 (es) 2006-02-02
EA011634B1 (ru) 2009-04-28
ECSP066833A (es) 2006-11-24
ATE432273T1 (de) 2009-06-15
TW200602313A (en) 2006-01-16
US7514458B2 (en) 2009-04-07
US20070142371A1 (en) 2007-06-21
EP1725544A1 (en) 2006-11-29
US7214802B2 (en) 2007-05-08
DE602005014621D1 (de) 2009-07-09
CY1109333T1 (el) 2014-07-02
AR048315A1 (es) 2006-04-19
ES2327940T3 (es) 2009-11-05
RS50796B (sr) 2010-08-31
MY143000A (en) 2011-02-14
WO2005090333A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
UA85702C2 (ru) 3-[ 4-гетероциклил-1,2,3-триазол-1-ил]-n-арилбензамиды как ингибиторы продуцирования цитокинов, предназначены для лечения хронических воспалительных заболеваний
WO2005108387A3 (en) Cytokine inhibitors
MY149577A (en) Cytokine inhibitors
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
UA100007C2 (ru) Гетероциклические ингибиторы мек, их применение и фармацевтическая композиция, которая их содержит
MXPA04004301A (es) Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa.
WO2007005668A3 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2005115991A8 (en) Anti-cytokine heterocyclic compounds
AU2003224923A1 (en) Heterocyclic amide derivatives as cytokine inhibitors
AU2003294388A1 (en) 1, 2, 3- triazole amide derivatives as cytokine inhibitors
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
DE60318320D1 (de) Benzimidazolone und ihre verwendung als cytokininhibitoren
DE602005019893D1 (de) 2-arylcarbamoyl-indole als zytokinhemmer
WO2012078674A8 (en) Substituted indole/indazole-pyrimidinyl compounds
TW200602032A (en) Processes for the preparation of 2-cyano-3-naphthalene-1-yl-acrylic acid alkyl or benzyl esters
UA86051C2 (en) Substituted quinoline compounds
UY28792A1 (es) Compuestos heterocíclicos anticitocina
WO2006018842A3 (en) Inhibitors of p38-alpha kinase
TW200612897A (en) Processes for the preparation of 2-cyano-3-naphthalene-1-yl-3-phenyl-propionic acid alkyl or benzyl esters